Child-Resistant Packaging Requirements: PPPA, CFR 16, and What Triggers CR Compliance

Child-resistant packaging is a federal requirement for specific product categories in the United States under the Poison Prevention Packaging Act of 1970 (PPPA). It is not optional, it is not a best practice, and it is not satisfied by adding a warning label that says "keep out of reach of children." Non-compliance exposes brands to CPSC enforcement, product recall, civil liability, and potential criminal penalties.

This guide covers which products require child-resistant (CR) packaging, what the federal testing standards are, and how to source and specify compliant closures and structures.

The Poison Prevention Packaging Act

The PPPA was passed in 1970 and authorises the Consumer Product Safety Commission (CPSC) to require special packaging for household substances that present a hazard to children under five years old. The implementing regulations are codified at 16 CFR Part 1700.

The Act requires that covered substances be packaged in child-resistant packaging unless:

• A specific exemption applies
• The manufacturer requests a senior-friendly exemption (see below)
• The product is packaged in a single-use, non-child-resistant package at the consumer's request

Which Products Require Child-Resistant Packaging

The CPSC has issued regulations requiring CR packaging for the following categories (this is the authoritative list as of the regulations; always verify current requirements as the CPSC can add categories):

Pharmaceuticals:

• Aspirin preparations containing more than one adult aspirin strength tablet (325mg)
• Acetaminophen preparations
• Ibuprofen preparations
• Naproxen sodium preparations
• All prescription drugs (with exceptions for specific exempted forms)
• Controlled substances
• Iron-containing drugs and dietary supplements with 250mg or more of elemental iron per unit

Over-the-counter drugs:

• Methyl salicylate-containing preparations (more than 5% methyl salicylate)
• Diphenhydramine preparations (more than 66mg per unit dose)
• Lidocaine preparations (more than 0.5 gram lidocaine)
• Dibucaine preparations
• Naproxen preparations (more than 250mg naproxen per unit dose when intended for OTC use)

Household chemicals:

• Controlled substances
• Ethylene glycol (antifreeze)
• Turpentine and mineral spirits preparations (greater than 10% concentration)
• Kindling or illuminating preparations (charcoal lighter, lamp oil)
• Paint solvents
• Methanol preparations
• Sodium and/or potassium hydroxide preparations (greater than 2% concentration)
• Drain cleaners containing lye

Dietary supplements:

• Iron-containing supplements with 250mg or more of elemental iron per unit dose. Note: the threshold is per unit dose, not per container. A supplement with 18mg iron per tablet is not covered; a product with 325mg iron per tablet is.

Cannabis/marijuana (state law, not federal): Cannabis is not covered by the PPPA at the federal level (it remains a Schedule I controlled substance federally). However, virtually every US state that has legalised recreational or medicinal cannabis has enacted its own CR packaging requirement. These state requirements vary but typically mandate CR packaging for all cannabis products sold to consumers, including edibles, tinctures, vape cartridges, and dried flower.

What Child-Resistant Actually Means: The Testing Protocol

CR packaging must pass the testing protocol specified at 16 CFR 1700.20. This is a two-part test:

Part 1: Child panel. The package is given to 200 children between 42 and 51 months of age (3.5 to 4.25 years old). The children are given five minutes to try to open the package; those who fail in five minutes get a second five-minute attempt with a demonstrated hint (showing the child how the closure works, without demonstrating the opening motion). The package passes the child panel if fewer than 20% of the children successfully open the package within the combined ten minutes.

Part 2: Adult panel. The package is given to 100 adults aged 50–70 years old. The adults have five minutes to open and reseal the package. The package passes the adult panel if 90% or more of adults can open and reseal it within five minutes.

Both tests must be passed for a packaging system to be certified as CR. A closure or package that is child-resistant but that 40% of seniors cannot open is not compliant.

The testing must be conducted by an accredited third-party laboratory. Common accredited CR testing labs in the US include ILS (Intertek), SGS, and Element Materials Technology.

Types of CR Packaging

Palm-and-turn closures. The most common CR closure for bottles and jars. The cap must be pressed down and simultaneously turned to open — a two-motion combination that requires coordinated hand strength most children under five cannot execute. These are the standard for pharmaceutical bottles and OTC medication.

Squeeze-and-turn closures. The closure has two opposing squeeze points that must be depressed while turning. Common on larger plastic containers for household chemicals.

Push-down-and-turn closures. Common for unit-dose packaging — foil blisters, vials. The foil or membrane must be depressed before the unit can be extracted.

Blister packs (unit-dose). Child-resistant blister packs require the user to push through a foil backing to release the tablet. The foil backing is chosen to require more force than most children can apply, while remaining accessible to adults. CR blister packs must still pass the 16 CFR 1700.20 protocol.

Cannabis-specific CR formats: Many cannabis brands use CR exit bags (mylar pouches with a specialised CR zipper closure), CR pop-top tubes (the standard for dried flower), and CR plastic jars (similar mechanism to pharma bottles).

Exemptions and Senior-Friendly Packaging

Single-use and senior-friendly exemptions. A manufacturer or packer may request that a product be available in a non-CR package. Two mechanisms exist:

1. Consumer request at retail. Pharmacies can dispense prescription medications in non-CR packaging at the specific, documented request of an adult consumer.

2. One-size non-CR package. Manufacturers may market one package size of a covered OTC product in non-CR packaging, provided all other sizes are in CR packaging and the non-CR package bears the statement: "This package for households without young children."

Mouthwash and certain other products: Some product categories that might otherwise seem covered have specific exemptions in the regulations. Always review the current 16 CFR Part 1700 regulatory text for the most current list.

How to Source CR-Compliant Closures

For most brands, the path to CR compliance is using a closure or packaging system that has already been tested and certified by the component supplier, rather than independently testing a custom packaging system.

Closure suppliers with CR certifications: Most major pharmaceutical closure suppliers (Aptar, Berry Global, Silgan, Gerresheimer) carry tested and certified CR closure lines. When ordering closures from these suppliers, request documentation of CR certification — specifically, the test report showing compliance with 16 CFR 1700.20.

Critical specification point: CR compliance applies to the complete packaging system — the container and the closure together as a unit. A certified CR closure on an incompatible container neck finish (wrong neck size, wrong material combination) may not perform as certified. Always confirm the closure has been tested on the specific container type you are using, or arrange testing of the complete system.

CR testing for new structures: If developing a novel packaging format that does not use an off-the-shelf certified closure system, independent CR testing by an accredited lab is required. Budget approximately $8,000–$20,000 for a full CR testing protocol and allow 8–14 weeks.

Labelling Requirements for CR Packaging

Under PPPA regulations, packaging subject to the PPPA must bear the statement: "Keep out of reach of children" or its equivalent. This statement must appear on the immediate container label, not just on the outer carton.

For products with CR closures, some brands additionally include the instruction for how to open the CR closure — for example, "Press down and turn" for palm-and-turn closures. While not universally required by regulation, this reduces consumer confusion and reduces calls to customer service.

State Cannabis CR Requirements

Because cannabis regulatory schemes are state law, CR requirements vary by state. However, the following elements are broadly consistent across most state schemes:

• All cannabis products sold in consumer-facing retail must be in CR packaging
• CR packaging is typically defined by reference to 16 CFR 1700.20 (same CPSC standard)
• Exit bags (secondary CR bags provided at point of sale) are often accepted as an alternative to primary CR packaging in some states
• Multi-use packaging (for products a consumer opens and recloses) must remain CR-functional after the first opening — meaning the CR mechanism must still function correctly when the package is reclosed and reopened
• Child-resistant requirements apply to edibles, beverages, topicals, tinctures, and vape products, not only dried flower

FAQ

Does my supplement require child-resistant packaging? It depends on the iron content. Dietary supplements containing 250mg or more of elemental iron per unit dose require CR packaging under the PPPA. Most standard multivitamins and iron supplements (which contain 18–65mg elemental iron per tablet) fall below this threshold. Products marketed explicitly as high-dose iron supplements should be reviewed against this threshold carefully.

Can I use a shrink band instead of a CR closure? No. A shrink band is a tamper-evident device, not a child-resistant device. These are different regulatory requirements with different purposes. A tamper-evident seal shows whether the package has been opened; a CR closure makes the package difficult for children to open. They can coexist on the same package but do not substitute for each other.

What happens if I sell a product that requires CR packaging without CR packaging? CPSC has authority to seek recalls, issue civil penalties, and refer criminal cases for wilful violations. Civil penalties under the Consumer Product Safety Act can reach $100,000 per violation and up to $15 million for a related series of violations. Class action exposure for products that cause harm is a separate risk.